Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 16, 2026
TickeronGET DAILY SIGNALS
Why Is CG Oncology (CGON) Stock Up 15.31% Today?

Why Is CG Oncology (CGON) Stock Up 15.31% Today?

Key Takeaways

  • CGON jumped $11.39, or 15.31%, to $85.79 in Monday afternoon trading, extending a premarket surge that briefly carried shares above $105.
  • The primary catalyst was positive topline data from the Phase 3 PIVOT-006 trial, in which cretostimogene cut the risk of bladder cancer recurrence by 68% versus surveillance.
  • Secondary drivers: a clean safety profile with no Grade 3 or higher treatment-related events, and plans to broaden the first FDA filing to cover high-grade papillary-only disease.
  • The move came against a sharply weaker tape, with the S&P 500 down about 1.9% and biotech broadly lower, underscoring the company-specific nature of the rally.
  • News Significance Score: 82/100 — Pivotal Phase 3 win, met by a move roughly six times the stock's typical daily swing.
  • Traders are watching the December 2 late-breaking presentation of full PIVOT-006 data, December durability readouts, and the revised March 2027 BLA timeline.
  • Investors seeking deeper detail can review Price Targets, Earnings, and Forecast pages for additional context.
  • Readers can also explore Trending AI Robots to see which automated strategies are performing best right now.

CG Oncology, Inc. (CGON) is a late-stage clinical biopharmaceutical company developing cretostimogene grenadenorepvec, an intravesically delivered oncolytic immunotherapy, as a bladder-sparing treatment for non-muscle invasive bladder cancer (NMIBC). Shares closed Friday at $74.40 and were last changing hands at $85.79, a gain of 15.31%, after the company reported that PIVOT-006 met its primary endpoint. The direction is unambiguously higher and the catalyst is verified: the release crossed the wire before Monday's opening bell, and the stock remains well above its prior 52-week high of $80.97 despite trading nearly $20 below its premarket peak.

PIVOT-006 Hits Its Primary Endpoint in a Population Without Approved Options

The pivotal readout is the whole story. In PIVOT-006, 367 patients with intermediate-risk and high-grade Ta tumors of 3 cm or less received adjuvant cretostimogene or underwent surveillance after complete tumor resection. Cretostimogene reduced the risk of recurrence by 68%, with a hazard ratio of 0.32 (95% CI: 0.23–0.45; p<0.0001) at a median follow-up of 17 months. No Grade 3 or higher treatment-related adverse events and no treatment-related discontinuations were reported.

The magnitude, not merely the statistical significance, drove the repricing. The trial was powered for roughly a 30% reduction in recurrence risk, and investors had generally penciled in something near 40%. A 68% effect cleared even the most bullish scenarios, and the company notes that this roughly 50,000-patient U.S. population has no FDA-approved adjuvant therapy. Management described the result as positioning cretostimogene as the first candidate to show a significant recurrence benefit in a pivotal Phase 3 trial in this setting.

Analyst Reaction: The Bar Was Cleared "By a Wide Margin"

Sell-side commentary reinforced the move. RBC Capital Markets analyst Leonid Timashev wrote that the data meaningfully exceeded both the trial's powering assumptions near 30% and investor expectations near 40%, noting that even in the firm's most constructive conversations, investors had not anticipated a reduction above 50%. He also argued the trial's history of enrollment delays likely reflected the drug's outperformance rather than operational problems, and flagged the non-chemotherapy profile as a potential commercial advantage over JNJ's Inlexzo. That framing turned a single dataset into a competitive-positioning argument on Monday.

A Later Filing Date Explains the Fade From the Premarket High

The intraday pattern is instructive. Shares touched $105.50 in premarket trading, opened at $92.00, and dropped to a session low of $80.75 within the first ten minutes before stabilizing. The offsetting item was regulatory timing: based on FDA feedback, CG Oncology will broaden its initial BLA in BCG-unresponsive NMIBC to include high-grade papillary-only disease, pushing completion from the fourth quarter of 2026 to before the end of March 2027. A second BLA from PIVOT-006 is targeted for the second quarter of 2027. The three-month slip is modest against a materially larger label, but it gave momentum traders a reason to book gains after a stock that had already risen about 79% year to date.

Market Context and Trading Activity

Participation was exceptional. Roughly 3.7 million shares had traded by mid-afternoon, versus a three-month average daily volume of about 1.0 million, comfortably more than triple normal turnover. The move was also sharply divergent from its backdrop: the S&P 500 fell about 1.9%, the biotech complex tracked by the XBI ETF dropped roughly 2.5%, and JNJ slipped nearly 1%. In other words, there was no sector or macro tailwind — the gain was entirely idiosyncratic.

Technically, the session delivered a gap-and-breakout above the prior 52-week high of $80.97 and the $37.01–$80.97 range that had contained the stock for a year. Holding above that former ceiling into the close would confirm the breakout; failure to do so would leave Monday's gap as an open question. Market capitalization now sits near $7.6 billion.

News Significance Score

The scale runs from 0, meaning no meaningful news and a routine move for the stock, to 100, meaning transformative news and an extreme, rare price move. This event scores 82 out of 100.

The news component is strong: a pivotal Phase 3 registrational trial met its primary endpoint with an effect roughly double the market's bar, in an indication with no approved therapy, and with clean safety. The price component is nearly as strong. Today's 15.31% advance is about 6.4 times the stock's average absolute daily move of roughly 2.4% over the past 60 sessions, and only one of those sessions produced a larger swing — the 17.3% gain on November 6. A pivotal win paired with a rare, high-volume move lifts the combined score into the low 80s rather than the 90s, since the filing delay and the fade from premarket highs trimmed the upside.

What Comes Next for CGON

The near-term calendar is dense. Full PIVOT-006 results will be presented as a late-breaking podium session at the Society of Urologic Oncology annual meeting on December 2, 2026, where investors will parse the high-grade versus low-grade contribution to the benefit. December also brings 12-month data from BOND-003 Cohort P and CORE-008 Cohort CX. On the regulatory side, completion of the BCG-unresponsive BLA is now targeted before the end of March 2027, with the PIVOT-006 filing in the second quarter of 2027; all BLA-enabling manufacturing work is complete, and roughly $984.5 million in cash is expected to fund operations through 2029. Fourth-quarter and full-year results are due in early 2027.

Risks cut both ways. The data so far are topline, the comparator was surveillance rather than an active agent, and the shares entered Monday after a long run. Any suggestion that the benefit concentrates in lower-grade patients, or a further slip in filing timing, would test the new valuation. Rivals including JNJ are also advancing in NMIBC, and commercial execution remains untested.

Trending AI Robots

Tickeron operates hundreds of AI trading bots spanning thousands of tickers, but its Trending AI Robots page curates only the strongest performers under current market conditions. Bots differ widely by strategy, timeframe, performance metrics and traded symbols, so the featured roster shifts as volatility and leadership rotate. For readers tracking catalysts like Monday's clinical readout, it offers a structured way to see which automated approaches are working now. Reviewing the current lineup is a practical next step.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CGON

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


CGON in upward trend: price rose above 50-day moving average on November 06, 2026

CGON moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend. In 28 of 30 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on CGON as a result. In 40 of 49 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.

The Moving Average Convergence Divergence (MACD) for CGON just turned positive on October 22, 2026. Looking at past instances where CGON's MACD turned positive, the stock continued to rise in 25 of 29 cases over the following month. The odds of a continued upward trend are 86%.

The 10-day moving average for CGON crossed bullishly above the 50-day moving average on November 11, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 82%.

Following a +20.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where CGON advanced for three days, in 119 of 149 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

The Aroon Indicator entered an Uptrend today. In 89 of 99 cases where CGON Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.

Bearish Trend Analysis

The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 34 of 39 cases where CGON's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 87%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CGON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.

CGON broke above its upper Bollinger Band on November 16, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 13 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.545) is normal, around the industry mean (3.586). P/E Ratio (-28.249) is within average values for comparable stocks, (-1.188). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. CGON’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 58 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CGON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.23B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -10%. For the same Industry, the average monthly price growth was -8%, and the average quarterly price growth was -22%. PEPG experienced the highest price growth at 75%, while ALGS experienced the biggest fall at -58%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -24%. For the same stocks of the Industry, the average monthly volume growth was 6% and the average quarterly volume growth was -35%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 43
Price Growth Rating: 65
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
Trend Prediction Engine 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
400 Spectrum Center Drive
Phone
+1 949 409-3700
Employees
142
Web
https://www.cgoncology.com
Interact to see
Advertisement
NVIDIA shares declined roughly 26% over the 30 days ending mid-November, falling from a close near $221 to $162.85. The drop left the stock about 30% below its October 6 record intraday high of $243.37 and at a 52-week low.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
Micron shares fell -6.28% to $729.40 from Friday's $778.31 close, gapping lower in premarket trading and holding those losses into Monday's regular session. The decline was sector-driven, not company-specific: memory peers SanDisk, SK hynix and Western Digital slid in tandem as last week's Nvidia CEO departure revived doubts over AI data-center spending, financing and memory demand durability.
SKHY fell -6.87% to $122.74 by 10:04 a.m. ET, down $9.05 from Friday's close of $131.79, extending a premarket decline into the regular session. The drop was driven by a sector-wide AI chip selloff ahead of Nvidia's quarterly results on Tuesday, where CEO Jensen Huang's resignation has raised doubts about the durability of data-center spending that underpins high-bandwidth memory demand.